More than a lonca-shot: beating the odds in relapsed/ refractory diffuse large B-cell lymphoma

Affiliations

¹ Division of Hematology and Oncology, Department of Internal Medicine, University of Washington, Seattle, WA, USA; Fred Hutchinson Cancer Center, Seattle, WA.
² Division of Hematology and Oncology, Department of Internal Medicine, University of Washington, Seattle, WA, USA; Fred Hutchinson Cancer Center, Seattle, WA. ssmith50@fredhutch.org.

Editorial

Carrie Ho et al. Haematologica. 2024.

. 2024 Apr 1;109(4):1022-1024.

doi: 10.3324/haematol.2023.284056.

¹ Division of Hematology and Oncology, Department of Internal Medicine, University of Washington, Seattle, WA, USA; Fred Hutchinson Cancer Center, Seattle, WA.
² Division of Hematology and Oncology, Department of Internal Medicine, University of Washington, Seattle, WA, USA; Fred Hutchinson Cancer Center, Seattle, WA. ssmith50@fredhutch.org.

No abstract available

Figures

Loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma: long-term efficacy and safety from the phase II LOTIS-2 study.
Caimi PF, Ai WZ, Alderuccio JP, Ardeshna KM, Hamadani M, Hess B, Kahl BS, Radford J, Solh M, Stathis A, Zinzani PL, Wang Y, Qin Y, Wang L, Xu ZC, Carlo-Stella C. Caimi PF, et al. Haematologica. 2024 Apr 1;109(4):1184-1193. doi: 10.3324/haematol.2023.283459. Haematologica. 2024. PMID: 37646659 Free PMC article. Clinical Trial.

1. Caimi PF, Ai W, Alderuccio JP, et al. . Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2021;22(6):790-800. - PubMed
1. Salles G, Duell J, González Barca E, et al. . Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study. Lancet Oncol. 2020;21(7):978-988. - PubMed
1. Kalakonda N, Maerevoet M, Cavallo F, et al. . Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial. Lancet Haematol. 2020;7(7):e511-e522. - PubMed
1. Thieblemont C, Phillips T, Ghesquieres H, et al. . Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I/II trial. J Clin Oncol. 2023;41(12):2238-2247. - PMC - PubMed
1. Dickinson MJ, Carlo-Stella C, Morschhauser F, et al. . Glofitamab for relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2022;387(24):2220-2231. - PubMed